United BioSource Acquires Abt Bio-Pharma Solutions
United BioSource Corporation (UBC)
announced the acquisition of
Abt Bio-Pharma Solutions, Inc.
(ABS), a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries.
The acquisition of ABS is part of UBC’s ongoing strategy to build a “best in class” portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies. With this acquisition UBC further expands its team of senior experts in comparative effectiveness and comparative value; increases its registry and observational study practices; and reinforces its commercial strategy and market access capabilities.
“UBC is an ideal home for ABS,” said Abt Associates Chief Executive Officer Kathleen Flanagan. “We are gratified to see our colleagues join an organization that shares our values. At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support the development and commercialization of their products.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
